Evidence map›Paper›PMID 35109906›Full record

Trial reportTrials2022

Treatment of Impetigo with Antiseptics-Replacing Antibiotics (TIARA) trial: a single blind randomised controlled trial in school health clinics within socioeconomically disadvantaged communities in New Zealand.

Sarah Primhak, Alicia Gataua, Diana Purvis, John M D Thompson, Cameron Walker, Emma Best, Alison Leversha

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Centering Indigenous voices in health.The Lancet regional health. Western Pacific · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sarah PrimhakPaediatric Infectious Diseases, Starship Children's Health, Auckland, New Zealand. Spri856@aucklanduni.ac.nz.ORCID http://orcid.org/0000-0002-6464-5217
Alicia GatauaNational Hauora Coalition, Auckland, New Zealand.
Diana PurvisPaediatric Dermatology, Starship Children's Health, Auckland, New Zealand.
John M D ThompsonUniversity of Auckland, Auckland, New Zealand.
Cameron WalkerUniversity of Auckland, Auckland, New Zealand.
Emma Best *Paediatric Infectious Diseases, Starship Children's Health, Auckland, New Zealand.
Alison Leversha *Community Paediatrics, Starship Children's Health, Auckland, New Zealand.
University of Auckland · NZStarship Children's Health · NZ

Funding

Auckland DHB Charitable Trust (A+ Trust) 9664Cure Kids New Zealand 4000
6 · The paper itself

Abstract

backgroundImpetigo is a common and contagious bacterial skin infection, affecting children worldwide, but it is particularly prevalent in socioeconomically disadvantaged communities. In New Zealand, widespread prescribing of the topical antibiotic fusidic acid had led to an increase in antimicrobial resistance of Staphylococcus aureus. Alternative treatments are urgently being sought, and as impetigo is a superficial infection, it has been suggested that topical antiseptics such as hydrogen peroxide or simple wound care alone may treat impetigo while avoiding the risk of increased antimicrobial resistance.

methodsThis protocol for a non-inferiority, single-blind randomised controlled trial compares topical fusidic acid with topical hydrogen peroxide and with simple wound care in the treatment of childhood impetigo. Participants are randomised to one of the three treatments for 5 days. The primary outcome is clinical improvement assessed through paired photographs analysed by graders blinded to treatment arm. The trial is based in school health clinics in an urban centre in New Zealand. Comparison of antimicrobial resistance patterns pre- and post-treatment is also performed. DISCUSSION: Special note is made of the need to involve the communities most affected by impetigo in the design and implementation of the clinical trial to recruit the children most in need of safe and effective treatments.

trial registrationAustralian New Zealand Clinical Trials Registry (ANZCTR) 12616000356460 . Registered on March 10, 2016  Protocol amendment number: 05 EB and AL contributed equally as senior authors.

Indexed as

Anti-Infective Agents, LocalImpetigoAnti-Bacterial AgentsAustraliaChildHumansNew ZealandSchoolsSingle-Blind MethodAnti-Bacterial AgentsAnti-Infective Agents, Local

Identifiers

PMID35109906
PMCPMC8812233
OpenAlexW4210674516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.